Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIST4721 in Hidradenitis Suppurativa
NCT05348681Phase 2Terminated
- Sponsor
- Aristea Therapeutics
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing RIST4721 400 mg with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 12 weeks and Incidence of Serious Adverse Events at 12 weeks. Started Jul 2022; status: terminated.
02
Drugs
vimnerixin
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05348681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348681.